This update was originally posted by MassBio CEO & President Kendalle Burlin O’Connell on LinkedIn:
SBIR reauthorization is heading to the President’s desk. That’s a meaningful win after months of uncertainty for the early-stage companies and startups that power Massachusetts’ innovation economy, but it’s just one thread in a week dominated by competitiveness questions, from China’s expanding role in the drug development pipeline to NIH’s vision for the next five years.
SBIR Reauthorization Heads to the President: After months of advocacy and sustained engagement on Capitol Hill, the Small Business Innovation Research and Small Business Technology Transfer (SBIR/STTR) programs are heading to the President’s desk for signature following passage in the House this week. This is a significant win for MassBio and the Massachusetts life sciences ecosystem after nearly 6 months of the critical programs pause. A long-term reauthorization through 2031 gives early-stage companies the stability they need to plan around non-dilutive federal funding. We’ll be monitoring for how quickly programs are able to start back up and will keep members apprised.
Congress’s Focus on China’s Biotech Growth: The House Select Committee on the Chinese Communist Party held a hearing this week examining China’s growing dominance across the drug development pipeline and generic drug supply chain. Witnesses, including MassBio Board Member Jacob Becraft, described a concerning feedback loop: as early-stage clinical trials migrate to China where trial costs are lower and enrollment is faster, the capital, infrastructure, and expertise follow. Committee members from both parties signaled clear interest in acting, with discussion focused on streamlining U.S. institutional review board processes, empowering investigator-initiated trials, and addressing the fact that active pharmaceutical ingredients for roughly a quarter of U.S. generics now originate in China.
China Focus Continues Next Week on Hill: The China-focused hearing activity on Capitol Hill doesn’t stop there. Next week, the House Small Business Committee will hold a hearing titled “Defending Main Street: Combating CCP Threats to America’s Small Businesses” on March 25, and the House Education and Workforce Committee will examine “U.S. Universities Under Siege: Foreign Espionage, Stolen Innovation, and the National Security Threat” on March 26. While neither hearing is centered specifically on biopharma, both touch on issues directly relevant to the life sciences ecosystem, from the small businesses and startups that drive early-stage innovation to the research universities that anchor the U.S. biomedical pipeline. Taken together, this week’s Select Committee hearing and next week’s activity signal that China competitiveness has become a sustained, cross-committee priority in Congress. We’ll be monitoring both hearings and will share relevant updates next week.
NIH Director Bhattacharya Testifies Before House Appropriators: NIH Director Jay Bhattacharya appeared before the House Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies earlier this week, where he pledged that NIH will spend its full $48.7 billion budget before the close of fiscal year 2026, despite data showing the agency has awarded 74% fewer new competitive grants than the historical average at this point in the year. In his written testimony, Bhattacharya framed his tenure around three priorities: restoring public trust in NIH following COVID-19, advancing what he calls “Gold Standard Science” through a new reproducibility and replication initiative, and modernizing how NIH makes and oversees funding decisions. He also described a new unified framework guiding all institutes and centers, a simplified peer review process, and a policy ending foreign subawards in favor of independently tracked awards. The hearing comes as NIH simultaneously moves through the public input phase of its FY2027–2031 strategic plan – more on that below.
NIH FY2027–2031 Strategic Plan RFI Open Through May 16: NIH has released a Request for Information seeking public comment on the framework for its next strategic plan, covering fiscal years 2027–2031. The plan is organized around three priorities: advancing research across key areas; sustaining research capacity and workforce; and operating with scientific integrity and accountability. Notable elements discussed in a webinar outlining the strategic plan earlier this week include an emphasis on New Approach Methodologies (NAMs), geographic balance in grant funding, heightened oversight of international subawards, and integration of MAHA priorities and Dr. Bhattacharya’s Unified Funding Plan. MassBio plans to comment on the RFI in advance of the deadline on May 16, 2026.